艾拉普林的研究进展

摘要/Abstract

摘要：

抗菌药物耐药性已成为全球面临的主要健康威胁，临床迫切需要新的抗菌药物以应对革兰氏阳性耐药菌感染。艾拉普林（英文名iclaprim）是Arpida公司开发的抗革兰氏阳性菌新药，是一种二氢叶酸还原酶抑制剂，现已获批用于治疗革兰氏阳性菌的皮肤、软组织感染和院内获得性肺炎的临床试验，目前已完成III期临床试验。研究表明，艾拉普林具有良好的组织分布，在体内、体外均有良好的抗菌活性，抗革兰氏阳性菌活性非劣效万古霉素，不良反应发生率与万古霉素类似，无肾毒性，抗菌谱包括全部革兰氏阳性菌、部分革兰氏阴性菌、非典型病原体、卡氏肺孢子。艾拉普林因体内分布广、蛋白结合率高、肺内浓度、药物不良反应少、良好耐受性等特点，有望成为治疗革兰氏阳性耐药菌感染的治疗药物。本研究综述了艾拉普林药理学、抗病原微生物活性、抗菌活性、药代动力学等各方面的研究进展，旨在为开发和治疗革兰氏阳性耐药菌感染的新兴治疗药物提供借鉴。

关键词: 艾拉普林, 革兰氏阳性耐药菌, 皮肤感染, 软组织感染, 医院获得性肺炎。

Abstract:

Antibiotic resistance is an ever-increasing global threat to public health by jeopardizing the treatment of infectious diseases. An emergency demand for new mechanism antimicrobial agents have been launching to effectively treat the infections caused by resistant strains.Iclaprim a new Gram-positive bacteria drug developed by Arpida，a novel 2，4-diaminopyrimidine with potent rapidly bactericidal activity against Gram-positive pathogens.Its clinical trials have been approved for the treatment of skin and soft tissue infections and hospital-acquired pneumonia in Gram-positive bacteria and phase III trials have been completed.Studies have shown that Iclaprim has good tissue distribution， good antibacterial activity in vivo and in vitro， and Gram-positive bacteria activity is non-inferior to vancomycin. The incidence of adverse reactions is similar to that of vancomycin， no nephrotoxicity. The antimicrobial spectrum includes all Gram-positive bacteria， some Gram-negative， atypical pathogens and pneumocystis carinii. Because of its wide distribution in the body， high protein binding rate， high pulmonary concentration， less adverse drug reactions and good tolerance， Iclaprim is expected to become a therapeutic drug for the treatment of Gram-positive bacteria resistant bacterial infections.In this study， the pharmacological， antimicrobial， antimicrobial， and pharmacokinetics aspects of etopol were reviewed， to provide reference for the development and treatment of new therapeutic drugs for Gram-positive bacteria resistant bacterial infections.

Key words: , Iclaprim； Gram-positive bacteria； Skin infections； Skin structure infections； Nosocomial pneumonia

中图分类号:

R978

孙燕, 陈萍, 邢俊香.

艾拉普林的研究进展 [J]. 中国医药导刊, 2024, 26(5): 443-449.

SUN Yan, CHEN Ping, XING Junxiang.

Research Progress of Iclaprim [J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2024, 26(5): 443-449.

参考文献

［1］ WHO. Antimicrobial resistance global report on surveillance［EB/OL］.（2014-06）［2024-03-01］.https：//apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf？sequence=1&isAllowed=y.

［2］ Cornaglia G， Rossolini GM. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens［J］. Clin Microbiol Infect，2009，15（3）：218-223.

［3］ Centrers for Disease Control and Prevention. About Antibiotic Resistance［EB/OL］. （2022-10-05）［2024-03-01］.https：//www.cdc.gov/drugresistance/about.html.

［4］ The UK Prime Minister. Review on antimicrobial resistance antimicrobial resistance： tackling a crisis for the health and wealth of nations. London： review on antimicrobial resistance.2014［EB/OL］. （2016-05-01）［2024-03-01］. https：//amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.

［5］ David MZ， Daum RS. Community-associated methicillin-resistant staphylococcus aureus： epidemiology and clinical consequences of an emerging epidemic［J］. Clin Microbiol Rev， 2010，23（3）：616-687.

［6］ Liu C， Bayer A， Cosgrove SE， et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children［J］. Clin Infect Dis，2011，52（3）：e18-55.

［7］ Kalil AC， Metersky ML， Klompas M， et al. Management of adults with hospital-acquired and ventilator-associated pneumonia： 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society［J］. Clin Infect Dis，2016，63（5）：e61-e111.

［8］ Noviello S， Huang DB， Corey GR. Iclaprim： a differentiated option for the treatment of skin and skin structure infections［J］. Expert Rev Anti Infect Ther，2018，16（11）：793-803.

［9］ Filippone EJ， Kraft WK， Farber JL. The nephrotoxicity of vancomycin［J］. Clin Pharmacol Ther，2017，102（3）：459-469.

［10］ He J， Qiao WL， An Q， et al. Dihydrofolate reductase inhibitors for use as antimicrobial agents［J］. Eur J Med Chem，2020，195：112268.

［11］ Rich G， Mee B. Trimethoprim［J］. Med J Aust，1985，142（6）：350-352.

［12］ Kohlhoff SA， Sharma R. Iclaprim［J］. Expert Opin Investig Drugs，2007，16（9）：1441-1448.

［13］ Keshipeddy S， Reeve SM， Anderson AC， et al. Nonracemic antifolates stereoselectively recruit alternate cofactors and overcome resistance in S. aureus［J］. J Am Chem Soc， 2015，137（28）：8983-8990.

［14］ Oefner C， Parisi S， Schulz H， et al. Inhibitory properties and X-ray crystallographic study of the binding of AR-101， AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus［J］. Acta Crystallogr D Biol Crystallogr， 2009，65（Pt 8）：751-757.

［15］ Sincak CA， Schmidt JM. Iclaprim， a novel diaminopyrimidine for the treatment of resistant gram-positive infections［J］. Ann Pharmacother，2009，43（6）：1107-1114.

［16］ Oefner C， Bandera M， Haldimann A， et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity［J］. J Antimicrob Chemother，2009，63（4）：687-698.

［17］ Schneider P， Hawser S， Islam K. Iclaprim， a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria［J］. Bioorg Med Chem Lett，2003，13（23）：4217-4221.

［18］ Huang DB， Charrier C， Hawser S. Worldwide surveillance of iclaprim activity： in vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017［J］. Diagn Microbiol Infect Dis，2020，97（1）：115013.

［19］ Huang DB. The activity of the diaminopyrimidine dihydrofolate reducatase inhibitor， iclaprim， against Toxoplasma gondii in an in vitro model： a pilot study［J］. Diagn Microbiol Infect Dis，2021，99（4）：115296.

［20］ Huang DB， de Piano C， Magnet S. Evaluation of in vitro activity of iclaprim in combination with other antimicrobials against pulmonary pathogens： a pilot study［J］. Access Microbiol，2019，1（3）：e000027.

［21］ Bryant AE， Gomi S， Katahira E， et al. The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus［J］. J Med Microbiol，2019，68（3）：456-466.

［22］ Huang DB， Hawser S， Gemmell CG， et al. In vitro activity of iclaprim against Methicillin-Resistant staphylococcus aureus nonsusceptible to daptomycin， linezolid， or vancomycin： a pilot study［J］. Can J Infect Dis Med Microbiol，2017，2017：3948626.

［23］ Morrissey I， Maher K， Hawser S. Activity of iclaprim against clinical isolates of Streptococcus pyogenes and streptococcus agalactiae［J］. J Antimicrob Chemother，2009，63（2）：413-414.

［24］ Huang DB， Duncan LR， Flamm RK， et al. The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens［J］. Diagn Microbiol Infect Dis，2018，90（1）：64-66.

［25］ Laue H， Valensise T， Seguin A， et al. In vitro bactericidal activity of iclaprim in human plasma［J］. Antimicrob Agents Chemother，2009，53（10）：4542-4544.

［26］ Newton HJ， Ang DK， van Driel IR， et al. Molecular pathogenesis of infections caused by Legionella pneumophila［J］. Clin Microbiol Rev，2010，23（2）：274-298.

［27］ Morrissey I， Hawser S. Activity of iclaprim against Legionella pneumophila［J］. J Antimicrob Chemother，2007，60（4）：905-906.

［28］ Huang DB， Duncan LR， Edah YK， et al. In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018［J］. J Glob Antimicrob Resist， 2021，25：14-17.

［29］ Huang DB. Extracellular and intracellular activity of iclaprim against Listeria monocytogenes［J］. Int J Antimicrob Agents，2019，53（1）：106-107.

［30］ Laue H， Weiss L， Bernardi A， et al， Islam K. In vitro activity of the novel diaminopyrimidine， iclaprim， in combination with folate inhibitors and other antimicrobials with different mechanisms of action［J］. J Antimicrob Chemother，2007，60（6）：1391-1394.

［31］ Aliouat EM， Dei-Cas E， Gantois N， et al. In vitro and in vivo activity of iclaprim， a diaminopyrimidine compound and potential therapeutic alternative against pneumocystis pneumonia［J］. Eur J Clin Microbiol Infect Dis，2018，37（3）：409-415.

［32］ Jones RN， Biedenbach DJ， Sader HS. In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects［J］. Diagn Microbiol Infect Dis，2009，63（3）：339-341.

［33］ Kohlhoff SA， Roblin PM， Reznik T， et al. In vitro activity of a novel diaminopyrimidine compound， iclaprim， against Chlamydia trachomatis and C. pneumoniae［J］. Antimicrob Agents Chemother，2004，48（5）：1885-1886.

［34］ Noviello S， Magnet S， Hawser S， et al. In vitro activity of iclaprim against isolates in two phase 3 clinical trials （REVIVE-1 and -2） for acute bacterial skin and skin structure infections［J］. Antimicrob Agents Chemother，2019，63（4）：e02239-18.

［35］ Sader HS， Fritsche TR， Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates［J］. Antimicrob Agents Chemother，2009，53（5）：2171-2175.

［36］ Huang DB， Noviello S， Gemmell CG. Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model［J］. Access Microbiol，2019，1（7）：e000052.

［37］ Huang DB， Morrissey I， Murphy T， et al. Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres［J］. Eur J Clin Microbiol Infect Dis，2018，37（4）：673-678.

［38］ Brandt BAJSEHAJJSRIR. Pharmacokinetics and Metabolism of ［14C］Iclaprim Mesylate in the Marmoset.Conference： 8th international society for the study of xenobiotics Meeting［EB/OL］. ［2024-03-02］ https：//www.researchgate.net/publication/268136383_Pharmacokinetics_and_Metabolism_of_14CIclaprim_Mesylate_in_the_Marmoset.

［39］ Holland TL， O'Riordan W， McManus A， et al. A phase 3， randomized， double-blind， multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens （REVIVE-2 Study）［J］. Antimicrob Agents Chemother，2018，62（5）：e02580-17.

［40］ Huang DB， O'Riordan W， Overcash JS， et al. A Phase 3， randomized， double-Blind， multicenter study to evaluate the safety and efficacy of intravenous iclaprim Vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens： REVIVE-1［J］. Clin Infect Dis，2018，66（8）：1222-1229.

［41］ Huang DB， Noviello S， Balser B， et al. A pooled analysis of the safety and efficacy of iclaprim versus vancomycin for the treatment of acute bacterial skin and skin structure infections in Ppatients with intravenous drug use： phase 3 REVIVE Studies［J］. Clin Ther，2019，41（6）：1090-1096.

［42］ Brandt R IS， Mcburney A， et al. Pharmacokinetics of single and multiple doses of iclaprim given by intravenous Infusion in healthy volunteers. Conference： 3rd International Symposium on Resistant Gram-Positive Infections. Niagara-OnThe-LakeAt， Canada.Volume： Proceedings［EB/OL］. （2006）［2024-03-02］. https：//www.researchgate.net/publication/264860378.

［43］ Brandt BAJSJHSEHSRIR. Absorption， Pharmacokinetics， Metabolism and Excretion of Iclaprim Mesylate in Healthy Humans. Conference： 8th International International society for the study of xenobiotics Meeting［EB/OL］. （2007）［2024-03-02］.https：//www.researchgate.net/publication/268136472_Absorption_Pharmacokinetics_Metabolism_and_Excretion_of_Iclaprim_Mesylate_in_Healthy_Humans.

［44］ Andrews J， Honeybourne D， Ashby J， et al. Concentrations in plasma， epithelial lining fluid， alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim （AR-100） in healthy men［J］. J Antimicrob Chemother，2007，60（3）：677-680.

［45］ Patel N， Huang D， Lodise T. Potential for cost saving with iclaprim owing to avoidance of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections［J］. Clin Drug Investig，2018，38（10）：935-943.

快速检索引用检索图表检索高级检索